@Blasance They don't say this in January 2019 "Based on these findings, we extended our collaboration agreement with Yissum in order to deepen the understanding of NT219’s efficacy in overcoming tumors’ resistance to immunotherapy" A month later, remove them...... And a year later say in the annual report that not following the license agreement is a company risk. The attach reads more like if a major shareholder sells their shares, they under contractual obligation to pay us, the license holder, a 12% fee. It doesn't read like the License is terminated.